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Abstract: The role of organo-fluorine compounds in modern health, food and energy related 
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industries is widely-appreciated. The unique properties that fluorine imparts to organic molecules, 
stemming from its high electronegativity and stability when bound to carbon, finds it increasing 
being used in the development of new bioactivities. Around 25% of the current blockbuster drugs 
contain fluorine and this number is increasing to well above 30% for recent FDA approvals. In this 
Review we highlight a selection of the most successful organo-fluorine drugs, that have achieved 
blockbuster status, namely, sitagliptin (diabetes), sofosbuvir (hepatitis C), emtricitabine (HIV), 
glecaprevir/pibrentasvir (hepatitis C), elvitegravir (HIV), dolutegravir (HIV), bictegravir (HIV), 
efavirenz (HIV), enzalutamide (prostate cancer), aubagio (immunomodulatory) and paliperidone 
palmitate (schizophrenia). For each compound we discuss their discovery, their relevant disease 
state and how they are made, emphasizing the source of fluorine-containing moieties, and where 
known, their mode of action. 
 
1. Introduction 
Since the seminal development and introduction to the clinic of fludrocortisone (1) (Figure 1) [1] in 
1953, the synthesis of organo-fluorine compounds for medicinal chemistry has grown from a rare 
and highly specialized activity to a status now where selective fluorinations of lead compounds are 
explored de rigueur in all front line drug development programmes. The high electronegativity of 
fluorine, its ability to form stable bonds to carbon and its compact size, offer a greater range of 
isosteric replacements (eg F for H) or electronic tunability than any other element, and this has 
elevated the role of fluorine in all areas of bioactives discovery [2]. It is quite remarkable that 
fluorine-containing compounds now constitute around 25% of small molecule drugs in the clinic. 
Fluorine-scans and fluorine-editing are now fully embedded activities in medicinal chemistry 
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explorations and this is having a major influence in contemporary organic chemistry. The 
international methodology development community, largely based in academia, are increasingly 
turning their focus towards innovative approaches to incorporating fluorine and fluorine containing 
motifs into organic chemistry scaffolds. This is driven by the requirement of big pharma to generate 
more and more diverse chemical libraries, with a higher frequency of fluorinated entities, to 
accelerate innovation. This is a golden age and there is no sense that the fluorine boom has peaked 
and when and where it may level out in drug discovery.  
Although developments of organo-fluorine compounds in healthcare are relatively regularly 
reviewed [3] we are stimulated after a decade to provide an update to the 2010 article in the Journal 
of Fluorine Chemistry entitled “Fluorine in health care: Organofluorine containing blockbuster 
drugs” [4]. This article uniquely focused on the most successful fluorine containing drugs ‘by sales’ 
at that time. This particular focus appears to have been appreciated by those researchers and students 
reviewing the topic and complements other approaches which classify by structure, the frequency 
of organofluorine motifs, pharmacokinetic strategies, fluorine chemistry/methodology, disease 
states etc., and this overtly commercial criteria offers another angle for emphasising the impact and 
importance of organofluorine chemistry more generally.  
Those drugs, that during their product lifetime, attained the status of sales of $1.0 billion dollars 
or greater per annum are often referred to as “blockbuster drugs”, and in this Review we highlight 
the more recent entries of organofluorine drugs in this category. This should not of course be the 
only definition of the success of a medication. The Pfizer statin, Lipitor (2) which is used to prevent 
cardiovascular disease [4], was highlighted in the 2010 review [4] and is considered the most 
profitable drug of all time, with sales exceeding $120 billion during its patentable life time. It came 
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off patent in 2011, and at that time generic manufacturers began production and dramatically 
reduced its market value. Although Lipitor lost its position as a leading revenue generator, it remains 
amongst the most prescribed drug in the world (in 2019) and still an outstanding success in 
prophylactic healthcare. However the anticipation of sales through patent lifetimes is what drives 
innovation in the pharmaceutical industry and therefore we feel that this approach merits some 




Figure 1. Structures of fludrocortisone (1) and Lipitor (2).  
 
For the present review article, we have selected the current top twelve fluorine containing 
compounds, based on their sales rankings in 2018 or 2019. These include (Figure 2), teriflunomide 
(3) (immunomodulatory), sitagliptin (4) (diabetes), sofosbuvir (5) (hepatitis C), paliperidone 
palmitate (6) (schizophrenia), glecaprevir/pibrentasvir (7 and 8) (hepatitis C), elvitegravir (9) (HIV), 
enzalutamide (10) (prostate cancer), dolutegravir (11) (HIV), bictegravir (12) (HIV), emtricitabine 
(13) (HIV) and efavirenz (14) (HIV). Each compound is considered individually where their modes 
of action and then their synthetic routes are described, and with an emphasis on the source of the 




Figure 2. Top fluorine containing drugs by world sales in 2019.  
 
2.  Teriflunomide (AubagioTM)  
During the 1980s, an anti-inflammatory drug discovery program at Hoechst [5] led to the 
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development of leflunomide (15, other names: HWA 486 [6], HR486 [5], SU101 [7]). Further 
studies showed that leflunomide (15) is quickly converted to teriflunomide 3, (also known as A77 
1726 [5], SU0020 [7] or HMR1726 [8]) in vivo (in the intestinal mucosa and plasma) mainly by a 
nonenzymatic transformation as illustrated in Scheme 1. It is this metabolite that is responsible for 
the drugs bioactivity [5]. As a result, teriflunomide (3) was widely explored in place of leflunomide 
(15) in in vitro studies [6,9] and differences between the activities of 15 and 3 were rarely observed 
[10]. The main effect of teriflunomide (3) seems to be inhibition of dihydroorotate dehydrogenase 
[11] with an IC50 of 0.26 μM [12]. According to QSAR, the CF3 group serves as an electron-
withdrawing, hydrophobic group with low molar refractivity [13]. An X-ray crystal structure of the 
complex of teriflunomide with human dihydroorotate dehydrogenase demonstrated that the CF3 
group occupies a small hydrophobic cavity of the enzyme [14]. 
 
Scheme 1. The conversion of leflunomide (15) to teriflunomide (3). 
 
Dihydroorotate dehydrogenase is an enzyme necessary for de novo pyrimidine synthesis 
[5,11,15]. As its name suggests, it transforms dihydroorotate into orotate, which is transformed 
further into uridine monophosphate [5,15,16]. Through the use of salvage pathways, most cells 
access sufficient amounts of pyrimidine nucleotides to function and divide. However, activated 
lymphocytes require much higher levels of pyrimidine nucleotides to progress from cell cycle stage 
G1 through the S phase, requiring de novo pyrimidine synthesis too. As a result, inhibition of 
dihydroorotate dehydrogenase arrests activated lymphocytes in the G1 phase, inhibiting antibody 
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production in the case of B-cells and proliferation in the case of T-cells [5,16]. Other actions of 
teriflunomide have been reported too [9], but they are considered less important [5,16]. 
The selective immunosuppressing effect of 15 and 3 made them highly suited for the treatment 
of autoimmune diseases. Clinical trials demonstrated that leflunomide (15) was safe except for an 
indication of teratogenic and embryotoxic effects in animal studies, efficacious, and tolerable, and 
it was approved by the FDA in 1998 for the treatment of rheumatoid arthritis [5,16]. Notably, 
immunomodulation was achieved without increasing the risk of opportunistic infections, a 
complication of many deoxynucleotide synthesis inhibitors [5]. It was also found that thanks to 
strong serum protein binding (99.5%) and enterohepatic recirculation, metabolite 3 has a long half-
life (15 days), but it can be quickly removed with cholestyramine [5,16]. Later, teriflunomide 3 was 
developed independently as a drug. Clinical trials showed that teriflunomide 3 is efficient in the 
treatment of relapsing remitting multiple sclerosis, where tolerability and safety were similar to 
those of leflunomide, and it was approved by the FDA in 2012 [17]. In Europe, the Committee for 
Medicinal Products for Human Use initially concluded that teriflunomide, as a metabolite of 
leflunomide, could not be considered a new active substance, but this opinion was later revised. It 
is noteworthy that with time, the teratogenic and embryotoxic effects of 15 and 3 appear less serious 
than originally thought [18]. 
Future therapeutic areas under investigation for leflunomide and teriflunomide involve 
treatment of cytomegalovirus and BK virus infections [19], multiple myeloma [19], breast cancer 
[20], and lupus nephritis [21]. 
Synthetic routes to access teriflunomide can be classified into two main groups. The first starts 
with cyanoacetylation of 4-trifluoromethylaniline, and the resulting product 16 is then acetylated at 
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its active methylene group. Scheme 2 shows an example with DCC-mediated coupling followed by 
treatment with acetyl chloride and NaH [22]. Notably, the latter reagent combination was utilized 
in the first reported example of this synthetic pathway too [23]. Scheme 3 shows another example, 
where cyanoacetyl chloride is used, and isopropenyl acetate/NaOH performs the second step [24]. 
Scheme 4 demonstrates that acetic anhydride and NaOH is also efficient in acetylating 16 [25]. 
 
 
Scheme 2. Synthesis of teriflunomide 3 via a DCC-mediated coupling. 
 
 





Scheme 4. Synthesis of teriflunomide 3 via acetylation of 16. 
 
A related synthetic approach, shown in Scheme 5. reverses the order of these steps. That is, 
acetylation of ethyl cyanoacetate is accomplished initially, and then aniline is subjected to acylation 
by ethyl 2-cyanoacetoacetate 17 [26]. 
 
 
Scheme 5. Synthesis of teriflunomide 3 via 2-cyanoacetoacetylation. 
 
The first reported synthesis of teriflunomide used an alternative strategy involving 
isomerization of leflunomide [27]. The necessary leflunomide is obtained through the reaction of 4-
(trifluoromethyl)aniline with an appropriate derivative of isoxazole carboxylic acid 18 [28,29], 
although other approaches are known [23]. Scheme 6 shows two examples. The first involves a 
traditional synthesis (acylation with acid chloride 19 and then isomerization of 15 with base) [28] 
and the second is an interesting mechanochemical synthesis (activation of 18 with 1,1’-
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carbonyldiimidazole, isomerization of 15 under acidic conditions) [29]. Note that the traditional 
synthesis used 4-(trifluoromethyl)aniline both as the nucleophile and the base, making the process 
less economic. 
The sales for Teriflunomide (AubagioTM) in 2018, which is marketed by Sanofi-Aventis for the 
treatment of multiple sclerosis, were $1.67 billion dollars. 
 
 
Scheme 6. Syntheses of teriflunomide through isomerization of leflunomide. 
 
3. Sitagliptin (Januvia™, GlactivTM, TesavelTM) 
Sitagliptin (4) was developed by Merck as a dipeptidyl peptidase-4 (DPP4) inhibitor for the 
treatment of diabetes. Sitagliptin (4) (Figure 3) is a β-amino amide derivative containing a key 
trifluoromethylated triazolopyrazine moiety and 2,4,5-trifluorophenyl group, and notably it contains 
a stereogenic centre [30]. Structure-activity relationships (SAR) studies, varying substituents on the 
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phenyl ring and the fused heterocycle found an obviously increased DPP4 inhibitory ability with 
the introduction of fluorine atoms at the settled positions, where an IC50 value of 18 nM was 
observed for sitagliptin (4) [30]. Sitagliptin phosphate (Januvia™, GlactivTM, TesavelTM) received 
approval by FDA in October 2006 for the treatment of Type II diabetes [31]. Sitagliptin phosphate 
(Januvia™) earned receipts of $3.48 billion which ranked in the 29 best-selling drug in 2019. 
Sitagliptin/metformin is also available as a single pill under the brand name JanumetTM in USA since 
2007. 
 
Figure 3. Structure of sitagliptin (4) used to treat Type II diabetes. 
 
Merck reported a process for the preparation of sitagliptin (4) with triazolopyrazine 23 and β-
amino acid 28 as the key intermediates (Scheme 7) [32]. This method was suitable for production 
on a multi-kilogram scale. The synthesis started with the arylation of hydrazine with 2-
chloropyrazine. The resultant 2-hydrazinylpyrazine (20) was treated by trifluoroacetic anhydride 
(TFAA) to generate bis-trifluorohydrazide 21, which underwent an intramolecular cyclization 
reaction in the presence of super phosphoric acid, affording the trifluoromethyl triazolopyrazine 22. 





Scheme 7. Synthesis of intermediate 23 for the preparation of sitagliptin (4). 
 
The synthesis of β-amino acid 28 was shown in Scheme 8. An asymmetric Ru-catalyzed 
reduction of the carbonyl group on β-ketoester 24 is another illustration of the contribution of 
Noyori’s asymmetric methodology to the development of pharmaceutical processes. This 
asymmetric reduction is followed by ester hydrolysis to generate intermediate 25. A coupling 
reaction between carboxylic acid 25 and BnONH2 in the presence of EDC-HCl afforded 
hydroxamate 26, which was subjected to an intramolecular cyclization reaction to generate lactam 
27. The treatment of lactam 27 with HCl and then a hydrolysis under basic conditions, provided the 
key intermediate 28. Triazole 23 was then coupled to amino acid 28 in the presence of EDC-HCl 
and N-methylmorpholine (NMM) to afforded intermediate 29, which was finally converted into 
sitagliptin (4) via a Pd-catalyzed hydrogenation. It should be noted that Soloshonok and co-workers 




Scheme 8. Synthesis of sitagliptin (4). 
 
As a final note, we would like to point out that for the catalytic enantioselective reduction of 
ketone 24 to alcohol 25, enantiomer self-disproportionation (SDE) tests [34] were not conducted 




Sofosbuvir (5), previously named GS-7977, was developed by Gilead Sciences as an antiviral agent, 
and approved by the FDA as Sovaldi™ [36] for the treatment of hepatitis C virus (HCV) infection 
in 2013. It fast become one of the best-selling drug on the market with sales exceeding $10 billion 
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in 2014. Sofosbuvir (5), is a pyrimidine-based nucleotide analogue featuring four contiguous 
stereogenic centers. It contains an L-alanine moiety, a chiral phosphoramidate unit, a 2’-fluorinated 
ribose ring and a uracil base (Figure 4) [37]. Sofosbuvir is also the active component in antiviral 
drug combinations. HarvoniTM contains ledipasvir and sofosbuvir as ingredients, a combination also 
developed by Gilead Sciences and approved by the FDA in 2014 for treating hepatitis C [38]. 
HarvoniTM was the second best-selling drug on the market for the years 2015 and 2016 and 
collectively Sovaldi™ and HarvoniTM were grossing close to £20 billion per annum at this time. 
These drugs have become a victim of their own success in substantially suppressing the disease, and 
also as other products have entered the market, their impressive revenues have declined in the most 
recent years. EpclusaTM, another combination drug, this time with sofosbuvir and velpatasvir was 
approved in June 2016, for the treatment of HCV regardless of HCV genotype or liver disease 
severity [39]. EpclusaTM rapidly reached blockbuster status, earning $1.9 billion in 2019.  
 
Figure 4. Sofosbuvir (5) used to treat hepatitis C often also in combination therapies.  
 
The original synthesis of sofosbuvir (5) started from (R)-4-isopropyloxazolidin-2-one (30) with 
(3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyldihydrofuran-2(3H)-one (34) as the 
key intermediate (Schemes 9 and 10). Acylation of (R)-4-isopropyloxazolidin-2-one (30) with 2-
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fluoropropanoyl chloride afforded amide 31, which was subjected to a Ti-promoted aldol reaction 
with acrolein. An intriguing intramolecular cyclization of the aldol product 32 with NBS gave 
lactone 33, which was converted to alcohol 34 after treatment with KOH [40].   
Scheme 9. Synthesis of the key intermediate 34 in sofosbuvir synthesis.  
 
With the central ribose moiety substantially assembled, the remaining peripheral aspects of 
sofosbuvir 5 were introduced as illustrated in Scheme 10. Silyl ether protection of hydroxymethyl 
group of lactone 34 was followed by the 3’-O-benzyl-protection to generate intermediate 35. This 
lactone was then reduced and acetylated at the anomeric position in a stereospecific manner, 
affording lactol 36 now with four contiguous stereogenic centers. The introduction of the nucleotide 
base was initiated with a SnCl4-promoted reaction between lactol 36 and N-(2-
((trimethylsilyl)oxy)pyrimidin-4-yl)benzamide to give 37 and the hydrolysis completed the 
introduction of the uridine moiety. The pro-drug arm at the 5’-O ribose oxygen was introduced after 
TBS ether removal and followed by reaction with (2S)-isopropyl 2-
((chloro(phenoxy)phosphoryl)amino)propanoate (39) to generate phosphoramidate 40, a process 
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that occurs with high diastereoselectivity (92:8 dr). Finally, Pd-catalyzed deprotection released the 
desired sofosbuvir (5) [41].      
 
Scheme 10. Synthesis of sofosbuvir (5).  
 
5. Paliperidone palmitate (InvegaTM Sustenna TM) 
The history of paliperidone palmitate has its origins with risperidone (41), an atypical antipsychotic, 
a drug which was launched commercially in 1994 [42]. Risperidone (41) is highly potent but its 
therapeutic range is not so wide. Together with the extrapyramidal side effects associated with 
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risperidone overdose, this generated interest in a sustained or delayed release formulation for 
risperidone and related compounds [43]. In theory, such formulations decrease the risk of adverse 
side effects through reducing fluctuations in plasma concentrations [44]. 9-Hydroxyrisperidone or 
paliperidone (±)-42, the main metabolite of risperidone (41), emerged as more promising for such 
purposes, because it has a similar potency and pharmacological profile to its parent, however its 
elimination half-life is longer (20 h vs. 2–4 h) than risperidone [42,43]. The use of paliperidone 42 
also negates the effects of genetic polymorphism on risperidone metabolism [43]. The hepatic 
metabolism of paliperidone is not significant as it is excreted mostly unchanged through the kidney, 
making clinically relevant metabolic drug–drug interactions unlikely [44]. Interestingly, the pure R 
and S enantiomers of paliperidone 42 have qualitatively and quantitatively similar in vitro 
pharmacological activity [44]. The above efforts first led to FDA approval of racemic paliperidone 
(±)-42 in 2006 as an extended-release formulation using an osmotically controlled release oral 
delivery system. This enabled once-daily administration without initial dose titration [42,44]. 
Meanwhile, paliperidone palmitate (±)-6 was identified as a promising candidate for intramuscular 
depot formation [43]. Paliperidone (±)-42 becomes available in the body only after intramuscular 
hydrolysis of dissolved paliperidone palmitate (±)-6, but (±)-6 dissolves only slowly at the injection 
site thanks to its extremely low water solubility, a property that facilitates once-monthly dosing only 
[45]. Surprisingly, aqueous suspensions of (±)-6 performed better than more traditional oil 
suspensions [43]. After successful clinical trials, the FDA approved Invega® Sustenna® (an aqueous 
suspension of paliperidone palmitate for intramuscular injection) for the acute and maintenance 
treatment of schizophrenia in adults in 2009 [45]. Subsequent formulations have been licensed as 
Trinza (2015) and Trevicta (2016). All of the above molecules (Scheme 11) were developed by 
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Janssen Pharmaceutica, a subsidiary of Johnson & Johnson and collectively these drugs are grossing 
over $2 billion in sales in 2019.  
Both 41 and (±)-42 exert their antipsychotic activity via antagonism of serotonin 5-HT2A and 




Scheme 11. Structures of the antipsychotic drugs risperidone (41), paliperidone (±)-42, and 
paliperidone palmitate (±)-6. 
 
Paliperidone palmitate is obtained mostly via palmitoylation of paliperidone. The initial 
synthesis of paliperidone used 3-benzyloxy-2-aminopyridine which, in reaction with lactone 43 in 
the presence of POCl3, afforded heterocycle 44. Catalytic hydrogenation of 44 led to (±) alcohol 45 
which is then treated without purification with piperidine derivative 46 to generate (±)-42 as the 





Scheme 12. Early paliperidone (±)-42 synthesis. 
 
This synthesis suffered from various problems. The final step required chromatographic 
separation and the purities of products were not reported. This resulted in considerable interest in 
achieving improved syntheses [47-60] and led to the identification of typical impurities (risperidone 
41, ketone 47, phenol (±)-48, N-oxide (±)-49) as well as competing side reactions (e.g. formation of 
dechlorinated (±)-50 during hydrogenation). Scheme 13 shows these impurities (except compound 
41) and byproducts. It was found that performing the hydrogenation of 42 under acidic conditions 
suppressed dechlorination [51,56]. Formation of the ketonic impurity 47 from (±)-42 is enhanced in 
the presence of metal ions (especially iron and zinc). Therefore, active charcoal used in the 
crystallization steps must contain less than 200 ppm of individual metal cations and a neutral or 
alkaline pH value when dispersed in water [57]. After formation, impurity 47 can be reduced to 
paliperidone [53,55,58] or removed via basic treatment [60]. The latter process also eliminated 
phenol byproduct 48 [60]. N-Oxide (±)-49 is formed from paliperidone under oxidative conditions 
and even THF with >0.015% peroxide content is sufficient to induce its formation [60]. After 
heterocycle 44 formation and then hydrogenation, byproduct (±)-50 and impurity 51 formed, whose 
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removal during purification of (±)-45 reduces the content in the final product (±)-42 [60]. 
 
Scheme 13. Structures of impurities during paliperidone synthesis. Hydrogenation byproduct (±)-
50 and impurity 51 are present in intermediate (±)-45. 
 
The best yields and purities for the different steps are found in different publications. Following 
the original synthetic approach, the formation of 44 was the most effectively achieved as described 
by Dolitzky [47]. A high-yielding (98%) hydrogenation protocol of 44 was reported by Kankan et 
al., [51], but the purity of the resulting (±)-45 was only 90%. A one-pot transformation of 3-
(benzyloxy)pyridin-2-amine into (±)-45, as reported by Solanki et al., [60], was less productive but 
yielded a product of 99.5% purity. Changing the synthetic pathway such as the transformation of 52 
into (±)-45, without benzylation/debenzylation proved even more advantageous [58] as summarized 




Scheme 14. Improved synthetic approaches towards intermediate (±)-45 required for paliperidone 
synthesis. 
 
Scheme 15 shows three methods which were optimized for the efficient preparation of 
paliperidone (±)-42 from (±)-45 and the hydrochloric salt of 46, generating the product in good 
yields and high purity. The earliest method used the relatively expensive iPr2NEt as a base, and with 
two additives (NaI and nBu4NBr), and the work up required the precipitation of paliperidone tartrate 
to achieve the desired yield and purity [58]. By contrast, the second method had a more 
straightforward work up using K2HPO4 as the base and KI [59]. Finally the most suitable approach 
for reliability on a multikilogram scale used iPr2NH as the base and DBU as an additive, and this 




Scheme 15. Various methods for the final step in paliperidone 42 synthesis. 
 
Riva et al. reported a fundamentally different paliperidone 42 synthesis. This involved selective 
deprotonation of risperidone 41, followed by reaction with molecular oxygen (O2), followed by 
reduction of the formed hydroperoxide (Scheme 16) [61]. 
 
Scheme 16. Synthesis of paliperidone 42 via selective hydroxylation of risperidone. 
 
Paliperidone palmitate (±)-6 can be prepared easily from paliperidone (±)-42 through 
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palmitoylation. Palmitic acid and DCC [43,46] or palmitoyl anhydride [62] provide good results 
(Scheme 17), while direct acylation with palmitoyl chloride proved inferior [63]. The 9-O-
acetylated derivative of paliperidone can be purified more easily than its parent compound [64] 
suggesting that  a final purification of paliperidone palmitate may offer an approach but utilizing 
more readily available albeit less pure (±)-42, as illustrated in Scheme 17. 
 
Scheme 17. Palmitoylation of paliperidone to generate (±)-6. 
 
Alternatively, there is patent where intermediate (±)-45 was subjected directly to 
palmitoylation, and where substitution with amine 46 (HCl salt) constitutes the final step to 
paliperidone palmitate (±)-6, however the purities and yields of products are not given in any detail 
[65]. 
 
6. Glecaprevir/pibrentasvir (MavyretTM) 
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Glecaprevir (7), previously named ABT-493, was developed by AbbVie as a next-generation, orally 
administered drug for the treatment of hepatitis C virus (HCV) infection. It is a HCV NS3/4A 
protease inhibitor (PI). The compound is extremely active with in vitro IC50 values in the low 
nanomolar range across various HCV genotypes 1-6 [66]. Glecaprevir (7) is a stereochemically 
complex macrocyclic compound featuring several amino acid moieties, including tert-leucine, 
proline and 1-aminocyclopropanecarboxylic acid. In 2017, glecaprevir 7 and the HCV NS5A 
inhibitor pibrentasvir (ABT-530) 8 were approved under the trade name MaviretTM in USA and EU 
as a single tablet fixed-dose combination treatment of chronic HCV genotypes 1, 2, 3, 4, 5 or 6 [66]. 
MavyretTM (Glecaprevir/pibrentasvir) earned a total $2.89 billion sales in 2019. Both glecaprevir (7) 
and pibrentasvir (8) have a high degree of fluorination with four and five fluorine atoms respectively 
(Figure 5) [67,68].  
 
Figure 5. Structures of the HVC drugs glecaprevir (7) and pibrentasvir (8). 
 
Cink and co-authors from AbbVie Inc. successfully developed a process for the preparation of 
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glecaprevir (7) via ring-closing metathesis reaction, which was reported to produce a batch of 41 kg 
of glecaprevir [69]. Mono-Boc-protected amino ester 53 was progressed to the di-Boc intermediate 
54, and then the alkene moiety was oxidized to afford aldehyde 55 as a means to access the 
difluoromethyl group. The fluorination used DAST and the resultant difluoromethyl ester 56 was 
hydrolysed to the corresponding carboxylic acid 57 and was coupled with 1-methylcyclopropane-
1-sulfonamide to give sulfonamide 59 as a key intermediate (Scheme 18).  
 
 
Scheme 18. Synthesis of sulfonamide 59 used in the synthesis of glecaprevir 7.  
 
The terminal difluoroallyl olefin 65 is a precursor for the key metathesis reaction and was 
prepared as illustrated in Scheme 19. Accordingly α-hydroxyl ester 60 was oxidised to α-keto ester 
61 and was condensed with diaminobenzene to afford the quinoxaline 62, which was then 
progressed to chloro quinoxaline 63. An SNAr substitution reaction with Boc-protected 
hydroxyproline, as a free carboxylic acid, then afforded ether 64, and finally esterification with 
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concomitant deprotection gave ester 65 as an amine hydrochloride. 
 
Scheme 19.  Synthesis of intermediate 65 used in the synthesis of glecaprevir 7 .  
 
Another key building block 68 for the metathesis reaction was required as a single enantiomer 
and this was achieved by an enzymatic resolution of racemic acetate 66. This involved the selective 
hydrolysis of acetate 66 with Novozym 435 to generate an intermediate alcohol (not shown) by 
kinetic resolution. Workup involved treatment with triphosgene to afford chloroformate 67 as a 
single diastereoisomer, and this intermediate was then coupled with tert-leucine and treated isolated 
as its dicyclohexylamine salt 68. The free carboxylic acid moiety of 68 was now coupled with amine 
65 to produce 69 containing two remote terminal olefins and primed for a RCM reaction. This was 
achieved using Zhan 1B as a catalyst to generate macrocyclic ester 70. The ester moiety was 
hydrolysed to generate carboxylic acid 71, and which was coupled with sulfonamide 59 to furnish 




Scheme 20. The final steps for the synthesis of glecaprevir (7).  
 
Alternative approaches for the preparation of (1R,2S)-1-amino-2-vinylcyclopropanecarboxylic 
acid 57 by alkylation/cyclization of chiral nucleophilic glycine equivalents have also been 
developed [70].  
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The synthesis of glecaprevir 7 illustrates how the assembly of complex structures with high 
degrees of stereochemistry and peppered with fluorines, are no longer the daunting tasks that they 
used to be as synthesis methodology has developed.  
 
7. Elvitegravir 
Elvitegravir (9) is an anti-retroviral used in the treatment of HIV.  It was developed by Japan 
Tobacco, and licensed for worldwide production by Gilead Sciences (Figure 6) [71]. Elvitegravir 
was branded as Vitekta for single medication, and received clinical approval from the FDA in 2014 
[72]. The drug was recommended to be taken in combination with other anti-retrovirals including 
an HIV protease inhibitor and a pharmacokinetic booster, usually cobicistat or ritonavir. Such 
boosters inhibit metabolizing cytochrome P450 enzymes, and this combination offset elvitegravir 
metabolism improving bioavailability and half-life [73]. With a booster, elvitegravir can be taken 
once daily [74], however, the drug was voluntarily withdrawn as a single medication in 2017 and 
became available in Genvoya, a combination treatment. Genvoya is a four-drug combination that 
contains elvitegravir, cobicistat (a pharmacokinetic booster), emtricitabine and tenofovir disoproxil 
fumarate (nucleoside/nucleotide reverse transcriptase inhibitors). It was the 12th most successful 
drug commercially in the United States in 2018, clearing sales of $3.63 billion. 
 




Elvitegravir is an integrase strand transfer inhibitor (INSTI), which acts on HIV-1 integrase 
(IN) [75] and accordingly it suppresses integration of HIV-2 coded DNA into the host’s genome 
[76]. Integration takes place in three sequential steps, terminal 3’-DNA processing, DNA strand 
transfer and gap repair [77]. The IN enzyme catalyzes the first two of these steps [78]. The 3’-DNA 
processing step involves the hydrolysis of the two terminal 3’-nucleotides of the reverse transcribed 
HIV complementary DNA. The modified HIV coded DNA is then integrated into the host 
chromosome in the strand transfer step. Gap repair then completes the process, annealing the guest 
DNA in the hosts chromosome. The HIV-1 IN enzyme contains three carboxylic acid residues (D64, 
D116 and E152) in its active site, which are involved in catalyzing the strand transfer reaction. These 
residues secure two Mg2+ ions via the carboxylate groups, which are then directly involved in 
electrostatic interactions with the triphosphate esters of the nucleotide substrates [79]. INSTIs such 
as elvitegravir bind to the Mg2+ ions, and interrupt substrate binding [80,81].  
Elvitegravir (9) has a bicyclic carbamoyl 4-pyridone structure [80]. The aromatic ring with 
both chlorine and fluorine substituents give the molecule a hydrophobic tail, with a flexible linker 
connecting to the second ring system. The free carboxylate binds to Mg2+ ions in the active site of 
the HIV-1 IN [82]. Notably the 2-fluoro group was found to significantly improve inhibition of DNA 
stand transfer (IC50 = 43.5 nM) relative to the non-fluorinated analogue (IC50 = 1.6 M) indicating 
an impressive enhancement with fluorine [71].  
Elvitegravir (9) is administered as a single enantiomer. The basic patent procedure (Scheme 
21) for its synthesis starts from 2,4-difluorobenzoic acid (72) [83,84]. This is first aryl-iodinated 
with N-iodosuccinimide, and then converted to an acid chloride and then progressed with ethyl 3-
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(dimethylamino)acrylate to give acrylate 73. The dimethylamino group is replaced with (S)-valinol, 
and introduces a stereogenic centre. The enamine is then cyclized using potassium carbonate, 
following by silyl ether protection of the alcohol to form 74. A palladium-catalyzed Negishi 
coupling reaction through the aryl iodide with 2-fluoro-3-chlorobenzylzinc bromide gave 75. The 
ester was then hydrolyzed to form a carboxylic acid and the fluoroquinolone underwent a SNAr 
reaction with methoxide to generate elvitegravir 9 [71]. 
 
Scheme 21. Initial patent procedure for the synthesis of elvitegravir 9.  
 
8. Enzalutamide (XtandiTM) 
Enzalutamide 10 (Figure 7, previous names: RD162’, MDV3100) was discovered at the University 
of California [85] and developed by Medivation and Astellas Pharma [86]. It was approved by the 
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FDA for the treatment of metastatic castration-resistant prostate cancer after docetaxel therapy in 
2012 and before docetaxel therapy in 2014 [87]. The indication was further extended to non-
metastatic castration-resistant prostate cancer in 2018 [88] and to metastatic castration-sensitive 
prostate cancer in 2019. Enzalutamide 10 is effective, safe, and generally well-tolerated. The most 
common adverse effects are fatigue, nausea, and anorexia, however, seizures are rarely reported 
[88].  Enzalutamide (XtandiTM) achieved sales of $3.62 billion in 2018, marketed by Astellas 
Pharma and Pfizer. 
Enzalutamide 10 is an androgen receptor (AR) antagonist. The AR is located in the cell 
cytoplasm, but after binding its ligand (testosterone, dihydrotestosterone or other androgenic 
steroids) the receptor is translocated into the nucleus and forms a homodimer, which stimulates 
expression of various genes. Physiological responses mediated by this AR signaling include prostate 
growth and differentiation, and almost all prostate cancers depend on AR signaling. This discovery 
led to androgen deprivation therapy, which is especially important in the treatment of advanced or 
metastatic prostate cancers. Androgen deprivation can be achieved by surgical or medical castration 
(decreasing testosterone production of the testicles), by blocking androgen biosynthesis (decreasing 
testosterone production in body as a whole) or by androgen receptor antagonists like enzalutamide 
(interfering with binding of androgens to AR) [87,89]. 
It is common that patients’ response to androgen deprivation therapy declines after 18–36 
months, a progression to a castration-resistant form [87]. In most cases, castration-resistant prostate 
cancer still requires AR signaling to survive and resistance to androgen deprivation therapy is 
achieved via overexpressing AR [87-89] or production of mutant ARs which are not inhibited, but 
activated by the prescribed anti-androgen [90]. In order to avoid these problems, development of 
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enzalutamide 10 started from RU59063 (76) whose affinity to AR is only 3 times lower than 
testosterone and has high selectivity for AR over other nuclear hormone receptors. Since the 4-
cyano-3-trifluoromethylphenyl moiety present in 76 and the related 4-nitro-3-trifluoromethylphenyl 
moiety are common structural elements amongst nonsteroidal AR inhibitors, development focused 
on other parts of the molecule. It was found that the hydroxyalkyl motif of RU59063 can be replaced 
with a wide variety of 4-substituted phenyl groups without losing activity. Compound 77 with a 4-
tolyl group was chosen for further development. Changing the alkyl groups of the thiohydantoin 
ring led to compound 78, which was slightly more potent than 77 in vivo. However, 78 also has a 
short half-life with very quick clearance, which is attributed to its relatively high clogP value, and 
the fast metabolic oxidation of the Ar-CH3 group. Replacement of the methyl group with more polar 
motifs led to compound 79, which still suffered from poor pharmacokinetics. The suspected cause 
was metabolic oxidation of the electron-rich aromatic ring. To avoid this, the electron-withdrawing 
CONHMe group was attached directly to the ring and an electron-withdrawing fluorine atom was 
also introduced. The resulting compound 80 was quite potent and had a very good pharmacokinetic 
profile. Further development resulted in enzalutamide (10), which was slightly more active. Scheme 




Figure 7. Development of enzalutamide 10 showing previous lead candidates 76-80. In vitro IC50 
values are given in brackets.  
 
The first published synthesis of enzalutamide 10 had a number of drawbacks. Many toxic 
and/or corrosive reagents (CrO3, SOCl2, thiophosgene, acetone cyanohydrin) were used and the 
yield of the final step (creation of the thiohydantoin ring by the reaction of isothiocyanate 82 with 
an α-aminonitrile) was poor (25% was later improved to 51%) [85,91]. Medivation patented a better 
route in 2011, which solved many of the above problems. Aminonitrile 81 was converted to 
isothiocyanate 82 with thiophosgene as a key intermediate. 4-Bromo-2-fluorobenzoic acid 83 was 
transformed to N-methylamide 84 and which was converted to the N-arylated 2-aminoisobutyric 
acid. The resulting amino acid 85 was methylated to give ester 86 which, upon reaction with 




Scheme 22 Medivation’s route to enzalutamide (10). 
 
In 2015, Zentiva patented a slightly different and shorter synthesis. Amino acid 85 was 
obtained from the fluoro-nitrobenzoic acid 87 via amidation, reduction of the nitro group, and N-
alkylation with 2-bromoisobutyric acid. Reaction of isothiocyanate 82 with carboxylic acid 85 gave 
enzalutamide (10) together with its hydantoin analogue. Their highly similar physical-chemical 
properties makes the removal of the hydantoin impurity difficult, but formation of the byproduct 
can be suppressed with a phenol additive (Scheme 23), and the level of hydantoin in the final product 




Scheme 23. Zentiva’s route to enzalutamide (10). 
 
The reaction of compounds 82 and 85 can also be facilitated by BSA [N,O-
bis(trimethylsilyl)acetamide] (Scheme 24) [94]. 
 
Scheme 24.  Last step in the synthesis of enzalutamide 10. 
 
All of the above methods use thiophosgene, which is a highly toxic liquid. Alternatively, amine 
81 can be transformed into isothiocyanate 82 in a multistep procedure using NH4SCN, PhCOCl, 
and NaOH [95]. Isothiocyanate 82 can also be replaced with the related reagent methyl 
dithiocarbamate, which can be obtained from amine 81 in 2 steps (reaction with CS2 and DBU, 
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followed by treatment with MeI) [96]. 
 
9. Dolutegravir 
Dolutegravir (11) is also an HIV-integrase inhibitor and acts on the strand transfer step during HIV-
1 genome integration into the hosts chromosome (Figure 8) [97]. Dolutegravir was co-developed by 
GlaxoSmithKline and Shionogi and was approved for the clinic by the FDA in 2013 [98]. 
Dolutegravir 11 is highly potent, having an IC50 of 2.7 nM and an EC50 of 0.51 nM, and exhibits 
greater potency than elvitegravir [99]. Additionally, it has a terminal half-life of 14 hours [100]. 
Dolutegravir dissociates more slowly than elvitegravir from the integrase-DNA complexes [101]. 
All of this means that dolutegravir presents a higher barrier to resistance development in-vitro [102], 
and unlike Elvitegravir it does not need to be taken with a pharmacokinetic booster [103]. It is 
administered on its own by single, daily dose. As a result of these benefits, dolutegravir is currently 
on the World Health Organization’s list of essential medicines. 
 
 
Figure 8. Structure of dolutegravir.  
 
Dolutegravir 11 has also been developed as a component of the combination drug Triumeq 
[104]. Triumeq also contains the reverse transcriptase inhibitors, abacavir and lamivudine. Triumeq 
was developed by ViiV Healthcare and was approved by the FDA for use in the United States in 
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2014.  Triumeq is administered as a single tablet taken once daily and the treatment exhibits a high 
barrier to resistance. In 2018 it grossed sales of $4.4 billion. 
Dolutegravir 11 is primarily metabolized by uridine diphosphate glucuronosyltransferase 
(UGT1A1) and to a lesser extent by cytochrome P450 (CYP450) activity [105]. It does not inhibit 
or induce UGT1A1 or CYP450 enzymes at clinically relevant concentrations [106]. Dolutegravir 
has a tricyclic carbamole pyridine structure [80]. Like elvitegravir, dolutegravir contains a 
hydrophobic tail, in this case as a 2,4-difluorobenzyl moiety and it coordinates active site Mg2+ 
associated with  HIV-1 IN, through its enolisable oxygens [80].  
Dolutegravir 11 is prepared as a single diastereoisomer in an enantiomerically pure form. The 
original Shionogi synthesis (Scheme 25 and 26) described a 16 step protocol with an overall yield 
of 2%. In summary, etherification of maltol (90) gave 91 which was treated with ammonia to 
generate 4-pyridone 92. Selective bromination with N-bromosuccinimide gave 93 as a substrate for 
palladium-catalyzed carbonylation. The resultant ester 94 was protected and then oxidized to give 
pyridine N-oxide 96, in order to mediate an ortho-methyl oxidation by N-oxide acetylation and [3.3] 





Scheme 25. Synthesis of intermediate 98 in the base patent synthesis of dolutegravir 11.  
 
Intermediate 98 was progressed to amide 100 and the primary alcohol of 100 was sequentially 
oxidized to carboxylic acid 102. Esterification gave methyl ester 103, and then N-allylation afforded 
4-pyridone 104. Selective oxidative olefin cleavage, generated aldehyde hydrate 105. This hydrate 
was treated with (R)-3-aminobutan-1-ol, forming two acetal diastereoisomers. Diastereoselective 
aminal ring closure generated the (S,R)-diastereomer with high selectivity and this progressed an 
intramolecular attack of the amine onto the ester moiety, to form lactam 106. Debenzylation gave 




Scheme 26. Base patent synthesis of dolutegravir.  
 
An alternative route was developed by Micro Labs as illustrated in Scheme 27 [107]. Pyran 
107, previously prepared in a three-step protocol, was treated with 2,2-dimethoxyethanamine to give 
4-pyridone 108, which was progressed to amide 109. Acetal deprotection followed by treatment 
with (3R)-aminobutan-1-ol resulted in heterocyclisation and generated both stereogenic centers with 
the formation of intermediate 106. Unlike the route in Scheme 25, benzyl deprotection was achieved 
with TFA in DCM and the product, as a free carboxylic acid, was recovered by crystallization from 
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toluene. Treatment with sodium hydroxide in methanol gave sodium dolutegravir (110) as the active 
pharmaceutical ingredient [108].  
 
Scheme 27. Alternative synthesis to sodium dolutegravir 110 developed by Micro Labs.  
 
10. Bictegravir 
Bictegravir (12) is another HIV-1 integrase inhibitor (Figure 9). Like elvitegravir and dolutegravir, 
bictegravir inhibits the strand transfer step of integration of virally coded DNA into the hosts 
genome. The drug was developed by Gilead Sciences and is administered as a component of the 
combination drug Biktarvy, also developed by Gilead Sciences. Biktarvy contains the nucleoside 
reverse transcriptase inhibitors emtricitabine and tenofovir alafenamide in addition to bictegravir 
[109]. Bictegravir exhibits a high in-vitro barrier to resistance and also has a terminal half-life of 
around 18 hours, and as a consequence is not prescribed with a pharmacokinetic booster [110]. It is 
metabolized primarily by CY3PA and UGT1A1 [111]. Biktarvy was first approved for use in the 
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USA by the FDA in February 2018 and soon after for the EU in June 2018. Biktarvy grossed sales 
in its first year of $1.18 billion and then $4.7 billion in 2019, and appears to be on a steep trajectory 
in commercial terms.  
 
Figure 9. Structure of the HIV integrase inhibitor bictegravir 12.  
 
Bictegravir (12) is an INSTI, and like dolutegravir also contains a tricyclic carbamoyl 4-
pyridone structure. However, it is unique in that it has a peripheral bridged oxazepane ring with a 
methylene bridge [112]. This flexible ring is thought to contribute to the efficacy of bictegravir, as 
it allows the drug to readily adapt conformation, to changes in the geometry of the IN active site 
[113]. Bictegravir contains three stereogenic centres, and it also has a peripheral hydrophobic 
aromatic moiety common to this class of drugs. 
The patent synthesis for bictegravir developed by Gilead begins with 4-pyridone 111 as a 
precursor to aldehyde 112. Treatment with (1R,3S)-3-aminocyclopentanol (113) generates tricycle 
114. With three stereogenic centres in place, carboxylic acid 114 is progressed to amide 116 after 
coupling with 2,4,6-trifluorobenzylamine (115). Methyl ether cleavage with MgBr2 generated the 




Scheme 28. Original patent synthesis of HIV integrase inhibitor bictegravir 12.  
 
Gilead developed an improved seven-step route to bictegravir (Scheme 29) [108]. In this route 
Meldrum’s acid was reacted with activated methoxyacetic acid to generate acylated intermediate 
118 and then treatment with trifluorobenzylamine (115) resulted in β-ketoamide 119. Enamine 120 
was formed after reaction with 2,2-dimethoxyethan-1-amine, which then cyclized in a reaction with 
dimethyl oxalate to form 4-pyridone 121. The required bicyclic ring system was installed when 121 
was treated with the oxalate or benzoate salt of (1R,3S)-3-aminocyclopentanol, and this generated 




Scheme 29. Improved synthesis of HIV integrase inhibitor bictegravir 12 by Gilead Sciences.  
 
11. Emtricitabine  
Emtricitabine (13) is an L-oxathiolanyl nucleoside derivatives (Figure 10), which was developed as 
a nucleoside reverse-transcriptase inhibitor. Structure-activity relationships (SAR) disclosed that 
fluorine substitution at C5- of the cytosine moiety is essential for the anti-HIV activity (13, anti-
HIV-1 in PBM cells, EC50 = 1.3 nM). More than 2 x 103 fold lower activity was found when the 




Figure 10. Structure of emtricitabine (13) and related anti-HIV compounds.  
Emtricitabine (13) has been successfully used as an active ingredient in several blockbuster 
drugs. BiktarvyTM is a combination drug containing emtricitabine and two other active ingredients, 
bictegravir and tenofovir alafenamide, which was approved in 2018 as a complete regimen for the 
treatment of HIV-1 infection in adults [109]. In 2019, BiktarvyTM grossed $4.7 billion in sales 
(ranked 16). Emtricitabine 13 is also used as a component of other anti-HIV combination drugs, 
including Truvada (emtricitabine/tenofovir disoproxil fumarate, Gilead Sciences), Atripla 
(efavirenz/emtricitabine/tenofovir disoproxil fumarate, Gilead Sciences és and Bristol-Myers 
Squibb) and Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, Gilead Sciences). 
The process for the preparation of emtricitabine (13) is presented in Scheme 30 [115], and 
involves the key quaternary ammonium salt intermediate 124. Treatment of 5-hydroxy-
[1,3]oxathiolane-2-carboxylic acid menthol ester 122 and thionyl chloride in the presence of 
methanesulfonic acid and DMF, followed by substitution with 2-mercaptopyridine gave 
intermediate 123, which was N-alkylated with ethyl iodide to generate pyridinium 124. Introduction 
of the pyrimidine base in protected form gave 125, and then deacetylation gave free amine 126. The 
ester moiety was reductively cleaved with NaBH4 to afford the core structure which was formulated 




Scheme 30. Synthesis of the HIV reverse transcriptase inhibitor emtricitabine (13). 
An enzymatic kinetic resolution process has also been developed for the preparation of 
emtricitabine (13). The hydrolytic ester resolution of racemic (+/-)-2’3’-dideoxy-5-fluoro-3’-
thiacytidine butyrate (128) was successfully demonstrated using an immobilized cholesterol 
esterase (accurel PP). In this manner emtricitabine (13) was obtained in high enantioselectivity (98% 




Scheme 31. Enzymatic kinetic resolution of butyrate 128 as a last step in the preparation of 
emtricitabine 13. 
 
Such biocatalytic resolutions can be complicated by the SDE phenomenon [117] necessitating 
controlled SDE assays for the reliable determination of reported enantioselectivity values [118].  
 
12. Efavirenz 
Efavirenz (S)-14 (former names: L-743726, DMP-266) was discovered and developed by Merck as 
an anti-HIV medication (Figure 11) [119,120]. Clinical trials demonstrated good efficiency and 
tolerability and efavirenz was approved by the FDA in 1998 for the treatment of HIV-1 infections 
as a single drug (Sustiva®) [121]. In order to utilize synergistic effects and to reduce the development 
of drug resistance, it became more and more common to use combinations of anti-HIV drugs, 
preferably as fixed-dose drug combinations [122]. Examples of efavirenz-containing fixed-dose 
drug combinations are Atripla® (2006, efavirenz/emtricitabine/tenofovir disoproxil fumarate) [121] 




Figure 11. Structure of the anti-HIV therapy efavirenz 14. 
 
As a retrovirus, HIV-1 transfects its host with RNA that encodes all of the structural proteins 
and enzymes required for replication. During infection, the reverse transcriptase enzyme creates a 
double-strand DNA copy of the viral RNA. This DNA is then integrated into the host genome by 
the action of a virally encoded integrase enzyme which insert this foreign DNA with associated 
promoters and regulatory elements. The host cell can now efficiently express viral genes, with the 
capacity to synthesize more viral particles. Inhibition of HIV-1 reverse transcriptase is a viable 
strategy to suppress virus replication and the progress of HIV-1 infection [124]. Efavirenz is a non-
nucleoside reverse transcriptase inhibitor (NNRTI). Such compounds bind to an allosteric site (a 
hydrophobic pocket) of the enzyme, inducing a conformational change, which interferes with 
protein function [121,122]. The role of the fluorine atoms in efavirenz 14 is to increase the acidity 
of the carbamate moiety, which forms an important hydrogen bonding interaction with the protein 
[125]. 
The first published synthesis of efavirenz 14 started from 4-chloroaniline. After pivaloylation, 
a directed ortho-lithiation reaction with ethyl trifluoroacetate and hydrolysis gave amino-ketone 130. 
Scheme 32 illustrates an improved version of this process. Amino-ketone 130 is then treated with 
2-cyclopropylethynylmagnesium bromide or 1-lithio-2-cyclopropylacetylene, and ring closing of 
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the resultan adduct with 1,1’-carbonyldiimidazole, generates racemic efavirenz [119,126]. Later, N-
Boc-protected 4-chloroaniline (obtained via reaction of 4-chlorophenylisocyanate with tBuOH) was 
subjected to ortho-lithiation, followed by treatment with ethyl trifluoroacetate, nucleophilic addition 
of 1-lithio-2-cyclopropylacetylene, and nBuLi-promoted cyclization to obtain racemic efavirenz 14 
[127]. In both cases, efavirenz 14 was resolved into its enantiomers via its (–)-camphanoylated 
derivative [119,126,127]. 
In order to investigate more cost-effective syntheses, asymmetric approaches have been 
explored. Merck researchers discovered that nucleophilic addition of 1-lithio-2-
cyclopropylacetylene to generate 130 in the presence of chiral amino-alcohols offers some level of 
enantioselectivity [120], but better enantiomeric excesses were achieved with para-methoxybenzyl-
protected amino-ketone 131. The complete conversion of 131 required 2 equivalents of acetylide 
and 2 equivalents of the amino-alcohol. Using amino-alcohol 132, an outcome of 98% ee was 
achieved if the acetylide–amino-alkoxide solution was warmed to ca. 0 °C before cooling to –55 °C 
[128]. Without this cooling the ee dropped to 82% [120]. This was explained by the temperature-
dependent nature of lithium aggregates where equilibration near 0 °C generated the dimeric species 
133, which remained intact upon freezing and promoted the required enantioselective addition 
[120,128]. After alkynylation, amino-alcohol 132 was recovered in 98% yield from the aqueous 
phase and product 134 was transformed into efavirenz (S)-14 by cyclization mediated by the 
equivalent of phosgene and oxidative N-deprotection. After some further development [129], this 
route (Scheme 32) was used to obtain the necessary quantity of the drug for clinical trials, launch, 




Scheme 32. Asymmetric synthesis of efavirenz 14 using lithium amino-alkoxides. 
 
Merck also explored the use of organozinc compounds but their basicity was low. It was found 
that mixing dialkylzinc with 1 equivalent ephedrine-derived amino-alcohol 132 and 1 equivalent of 
achiral auxiliary alcohol in any order produced an organozinc species, which upon treatment with a 
lithium or magnesium acetylide generated a zincate, which participated in the required reaction, 
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with good efficiently and enantioselectivity. Optimized conditions gave 95% of analytically pure 
(S)-135 with an 99.3% ee after recrystallization. Amine-alcohol 132 can be recovered from the 
aqueous phase at workup, (Scheme 33). Interestingly, this new method requires the free aromatic 
amino group to achieve high ee values, as product 134 was formed only with 45% ee from 131 
[120,130]. 
 
Scheme 33. Key steps of the second asymmetric synthesis of efavirenz 14. 
 
Later, it was found that (S)-135 behaves as a catalyst in the alkynylation step, which supersedes 
the use of CF3CH2OH and enables reducing the amounts of ZnEt2 and 132. These autocatalytic 
conditions generated (S)-135 in a 79% yield and with 99.6% ee. After correction for the initially 





Scheme 34. Autocatalytic enantioselective alkynylation of ketone 130 in the synthesis of efavirenz 
14. 
 
Lonza patented an alternative synthetic pathway to efavirenez 14 in 2012, which does not 
require the N-protection and deprotection steps or the use of phosgene. In the first step 1,4-
dichlorobenzene was transformed into ketone 139 (ortho-lithiation then quenching the carbanion 
with methyl trifluoroacetate). In the asymmetric version of the Lonza pathway (Scheme 35), 
addition of an organozinc reagent derived from 2-cyclopropylacetylene, to ketone 139 in the 
presence of chiral aminoalcohol derivative 140, proceeded with moderate enantioselectivity (46%ee 
of (S)-141). In the racemic version of the pathway (not shown), 1-lithio-2-cyclopropylacetylene 
reacted with 139 to give (±)-141 in 84% yield. Both routes continued by creation of a carbamate 
motif using chlorosulfonyl isocyanate, followed by heterocyclic ring closure via an Ullmann 
reaction. Naturally, the racemic pathway requires a resolution, while the asymmetric route gave 




Scheme 35. The asymmetric version of the Lonza route to efavirenz 14. 
 
In 2015, Correia et al. published a concise synthesis of racemic efavirenz 14 using flow 
technology. The first two steps followed the Lonza pathway but by replacing methyl trifluoroacetate 
with N-trifluoroacetyl morpholine. The morpholine byproduct can be removed in-line with an acidic 
scavenger column, whereas the alcohol byproduct cannot. Note that both classes of by-products 
interfere in the next step. The final step (Scheme 36) is remarkable since (±)-141 was transformed 
into racemic efavirenz 14 in a single step (Cu-catalyzed N-aryl carbamate formation and cyclization). 
Since this step can also be performed under batch conditions, it may be possible to integrate it into 




Scheme 36. The last step in the flow synthesis of efavirenz 14 by Correia et al.. 
 
A more recent synthesis was published in 2016. In this case instead of enantioselective alkynide 
addition, cinchona-catalyzed enantioselective trifluoromethylation was used to prepare tertiary 
alcohol (S)-145 and Lonza intermediate (S)-141. The nitroaryl group of (S)-145 was readily reduced 
to aniline (S)-135 and it was then transformed further into efavirenz (S)-14. The conditions described 
by Correia et al. [134] to transform intermediate (S)-141 into efavirenz, were applied but without 
an argon atmosphere and sealed tube (Scheme 37). As a result only a 28% isolated yield was 




Scheme 37. Organocatalytic asymmetric synthesis of efavirenz 14. 
 
The tertiary stereogenic center in efavirenz 14 is of the kind that is known to display a 
significant self-disproportionation of enantiomers (SDE) phenomenon via achiral chromatography 
[135] and sublimation [136]. One of the complications of the SDE is an erroneous determination of 
the stereochemical outcome of enantioselective catalytic reactions. However, this property was not 




13. Conclusions.  
Fluorine is embedded in medicinal chemistry culture as a tool for refining structure activity 
relationships of lead compound scaffolds and for modulating pharmacokinetic properties. As a 
consequence of such activity, which takes place with intensity during drug development 
programmes, an increasing number of new chemical entities are emerging each year and receiving 
approval that containing fluorine. It has gone from a rather rare modification in the 1950s to an 
unexceptional one in contemporary pharmaceuticals development.  
It follows that there has been a notable broadening of interest in the development of new 
methods for the introduction of fluorine and fluorine containing motifs. Incorporating fluorine atoms 
can be costly particularly if scale up is required and thus a focus on process development and 
achieving efficient and environmentally satisfactory fluorination methods is currently among the 
most active fields in international organic chemistry at the moment. From the fluorine chemistry 
perspective innovation and focus has moved largely from materials and polymers to pharmaceuticals 
and bioactives over the last few decades.  
This review has taken a rather narrow snapshot [137], focusing on the current top selling 
fluorine containing drugs in the last 2 or 3 years, but it aims to illustrate the extraordinarily high 
commercial returns that can be gained from successful drugs particularly during their patent lifetime. 
This is what drives the pharmaceuticals industry and the increasing relevance of fluorine in this 
enterprise is driving innovation in fluorine chemistry.  
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